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Abstract
Background: Deep brain stimulation is increasingly used in the treatment of advanced Parkinson’s disease. While
its short-term effectiveness is well documented, there are only few reports on long-term outcomes, and the need
to repeatedly reprogram the stimulator is seldom reported.
Case presentation: We present a 74-year-old man with gait impairment, which had been mistaken for worsening
of the disease and only remitted when the stimulator battery was exhausted indicating that the stimulator itself
had been the cause.
Conclusion: This case highlights the need to repeatedly monitor not only battery capacity, but also stimulator-related
side-effects for an extended period after implantation and, if necessary, to refer to centres capable of systematically
reprogramming the device.
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Background
Deep brain stimulation is an effective method for redu-
cing off times and hyperkinesia in advanced stages of
idiopathic Parkinson’s disease [1, 2]. While there are
controlled long-term outcome studies that confirm the
on-going effectiveness of the treatment [3], the clinical
results outside of controlled trials are less well docu-
mented, and subjective outcome reports are occasionally
disappointing [4–6]. We present a striking example of a
patient who had been wheelchair-bound for years due to
stimulator-related side-effects. Once this was detected
by chance because of battery exhaustion, we were able
to partially improve his gait and speech clarity by repro-
gramming the stimulator.
Case presentation
A 74-year-old, retired teacher with a 20-year history of
idiopathic Parkinson’s disease had undergone bilateral
subthalamic nucleus (STN) deep brain stimulation
(DBS) in a centre with experience in the method. We
first saw him seven years after the implantation when he
presented in our clinic to have the device transiently
switched off for scheduled dental surgery. He was
wheelchair-bound outside his home and used a walking
frame at home. His caregiver reported that he fell fre-
quently, and he was dysarthric to an extent that almost
completely hindered oral communication. The UPDRS
III score was 32 of a possible 108 points; the DBS
settings were 130 Hz with 60 microseconds pulse width
and monopolar setting with the second deepest elec-
trode contact on each side acting as cathode and the
case acting as anode with an amplitude of 2.5 V in the
right and 3.0 V in the left hemisphere. He was on medi-
cation with levodopa, entacapone, and pramipexole
divided into seven daily doses, with a total levodopa
equivalent dose of 998 mg [7], oral quetiapine 25 mg at
night-time for his visual hallucinations, as well as oral
rivastigmine 3 mg in the morning for dementia. The
Kinetra® battery capacity was indicated as “OK” with a
voltage of 2,56 V and 40–90 % of the capacity used.
Five months after our first contact, the patient’s
caregiver contacted the first author and reported that the
patient was surprisingly able to walk independently, and
that the clarity of this speech had improved markedly. She
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also reported that the deep brain stimulator no longer
responded to the patient’s controlling device.
We confirmed that the battery was exhausted. He was
able to speak intelligibly with mild hypophonia. Rising
from chair was fast, but postural responses were
markedly reduced, resulting in a very unsteady, albeit
independent gait over a distance of several meters. The
UPDRS part III score was 24. He was now on medica-
tion with levodopa, entacapone and pramipexole every
four hours, with a total levodopa equivalent dose of
1182 mg, oral quetiapine 25 mg at night-time and a
rivastigmine patch 9 mg in the morning.
Expecting a relapse and worsening of the parkinsonian
symptoms in the foreseeable future, we implanted an
Activa PC ® device and left the stimulator off until his
clinical condition should worsen. To avoid falls, we
recommended that he walk only with assistance and
with a walking frame.
After a further four months the patient presented with
increasingly incapacitating fluctuations of motor func-
tion that made walking with the frame more and more
difficult, indicating further disease progression. The
other motor symptoms were stable except for a slight
worsening of his hypophonia and very poor postural
stability, resulting in a UPDRS part III score of 27. We
carefully retested the electrodes and opted for a bipolar
setting in the left hemisphere with contact 3 negative
and contact 2 positive at 3.5 V, and a monopolar setting
in the right hemisphere with the deepest contact 7 as
cathode and the case as anode at 2.0 V, with 130 Hz
frequency and 60 microseconds pulse width bilaterally.
We discharged the patient with less pronounced dyski-
nesias, and medication with levodopa, entacapone and
pramipexole in eight doses over the day, with a total
levodopa equivalent dose of 1182 mg, oral quetiapine
25 mg at night-time, and oral rivastigmine 3 mg three
times daily.
Conclusion
We report on a patient with an obvious post-operative
over-stimulation, which made him wheelchair-bound,
which was mistaken for disease progression and undetected
for years, also by ourselves at the initial presentation. An
incorrectly programmed stimulator was only recognized as
the cause when he was able to walk after the stimulator
battery had been exhausted.
We assume that internal capsule stimulation impaired
his walking. Over-stimulation causing internal capsule
stimulation was a frequent finding in a recent retro-
spective study on causes for dissatisfaction with STN
deep brain stimulation [6]. Slowly decreasing postopera-
tive microlesional effects [8], impedances changing over
months [9] or years [10] after surgery all evolve on pro-
longed time scales that are difficult to predict, and
influence the effects and side-effects of DBS. Disease
progression and the occurrence of axial and non-
dopamine-responsive symptoms further complicate the
clinical picture [11–14]. This extends the postoperative
stimulator optimization phase to 12 months [6]. Some
DBS centres advocate routinely rescheduling the patients
six or twelve months after surgery [8] in order to detect
secondary postoperative worsening of symptoms. Strat-
egies to reduce axial side effects include smaller stimula-
tion fields by bipolar settings [8], reduced stimulation
frequencies reported to be effective in some patients
[15–17], or interleaved stimulation of deeper electrode
contacts [18].
In summary, this case exemplifies the importance of
long-term postoperative stimulator programming to make
the full long-term potential of deep brain stimulation
available to the patient.
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